UCB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124.2 EUR | -0.64% |
|
+1.55% | +58.02% |
| 11/04 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
| 11/04 | UCB : Berenberg, Buy, raises its price target | CF |
| Sales 2024 * | 5.62B 6.03B 502B | Sales 2025 * | 6.33B 6.79B 566B | Capitalization | 23.12B 24.82B 2,069B |
|---|---|---|---|---|---|
| Net income 2024 * | 407M 437M 36.42B | Net income 2025 * | 852M 915M 76.24B | EV / Sales 2024 * | 4.41 x |
| Net Debt 2024 * | 1.64B 1.77B 147B | Net Debt 2025 * | 816M 876M 73.01B | EV / Sales 2025 * | 3.78 x |
| P/E ratio 2024 * |
58.4
x | P/E ratio 2025 * |
26.8
x | Employees | 8,767 |
| Yield 2024 * |
1.16% | Yield 2025 * |
1.19% | Free-Float | 61.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on UCB
More press releases
| 1 day | -0.64% | ||
| 1 week | +1.55% | ||
| Current month | +9.04% | ||
| 1 month | +8.00% | ||
| 3 months | +44.82% | ||
| 6 months | +78.60% | ||
| Current year | +58.02% |
1 week
120.35
125.00
1 month
113.75125.00
Current year
78.94125.00
1 year
65.68125.00
3 years
65.68125.00
5 years
61.32125.00
10 years
55.36125.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/11/01 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 57 | 01/20/01 |
| Chief Tech/Sci/R&D Officer | 63 | 01/17/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 28/16/28 | |
Dame Davies
BRD | Director/Board Member | 73 | 01/14/01 |
| Chief Executive Officer | 65 | 01/11/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 124.2 | -0.64% | 0 |
| 30/24/30 | 125 | +1.17% | 218 |
| 29/24/29 | 123.6 | +0.82% | 88 |
| 26/24/26 | 122.6 | +1.83% | 620 |
| 25/24/25 | 120.4 | -1.55% | 0 |
Delayed Quote Deutsche Boerse AG, May 02, 2024 at 11:40 am IST
More quotes
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
121.8
EUR
Average target price
125.5
EUR
Spread / Average Target
+2.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.44% | 86.16B | |
| +2.76% | 40.17B | |
| -17.49% | 31.47B | |
| -13.13% | 15.82B | |
| -9.12% | 11.96B | |
| -15.45% | 11.89B | |
| -42.56% | 11.61B | |
| +4.87% | 8.84B | |
| -4.09% | 7.93B |
- Stock Market
- Equities
- UCB Stock
- UNC Stock
